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ABSTRACT 
Objective: The principal objective of this research work was to formulate tioconazole into mucoadhesive microspheres which were inserted into 
the vagina for sustaining the anti-fungal activity and protecting the liver and the kidney from the harmful drug side effects.  
Methods: Microspheres were prepared by the emulsion solvent evaporation method, using different ratios of the drug with either ethyl cellulose 
N14 or hydroxypropylmethylcellulose K100M (HPMC K100M) as mucoadhesive polymers. The formulated microspheres were evaluated for the 
particle size, entrapment efficiency, yield percentage, mucoadhesion strength, swelling percentage, pH, in vitro release of the drug and finally in vitro 
antifungal activity.  
Results: The optimized formulae were F3 and F6, which showed drug entrapment of 88.4±2.5 % and 97.8±1.6 %, yield percentage of 85.0±2.3% 
and 95.2±1.2%, mucoadhesion strength of 31.5±1.6 and 38.1±1.6 *103 dyne/cm2, swelling percentages of 143.1±1.3 and 154.2±0.8, pH of 4.7±0.1 
and 4.6±0.5, and particle size of 400±3.5 µm and435±7. 8 µm respectively. F3 and F6 released about 72.8%±3.2 and 58.4%±2.7 of the drug after 8 h 
respectively. F3 and F6 showed a significant anti-fungal activity. 
Conclusion: Ethyl cellulose and hydroxyl propyl methylcellulose mucoadhesive microspheres are considered a good way to increase the duration of 
the anti-fungal activity of tioconazole with minimum side effects. 
Keywords: Microspheres, Tioconazole, Mucoadhesion, Vagina 




Vaginal cavity is an important and alternative area for the drugs that 
suffer from either first pass metabolism or extensive destruction in 
the stomach. Increased drug administration area, rich blood supply 
and poor enzyme activity, encourage the researchers to choose the 
vagina as a route for application of several drugs, especially those 
have harmful impacts on the liver and the kidney like imidazole anti-
fungal drugs [1]. 
Fortunately, mucoadhesive microspheres sustain the release of the 
drugs, enhance the bioavailability and increase the absorption due to 
the intimate contact with the vaginal mucosa [2]. Tioconazole is 
(RS)-1-[2-[(2-Chloro-3-thienyl) methoxy]-2-(2, 4-dichlorophenyl) 
ethyl]-1H-imidazole. It adversely affects both the kidney and the 
liver and suffers from poor bioavailability. 
Hani et al. formulated clotrimazole into intravaginal microspheres 
by the spray drying technique, which was inserted into a 
mucoadhesive gel for the local treatment of vaginal candidiasis [3]. 
Kalita et al. increased the vaginal residence time of metronidazole 
through the preparation of PLC microspheres, which were 
incorporated into carbopol 934p and HPMC K4 M bioadhesive gel 
[4]. Khan and Thakur developed novel chitosan mucoadhesive 
microspheres for vaginal administration of tenofovir disproxil 
fumarate [5]. The principal intention of this research study was to 
formulate vaginal mucoadhesive microspheres loaded with 
tioconazole to avoid the harmful impacts of the oral administration 
of the drug on the kidney and the liver and enhancing its poor oral 
bioavailability through increasing the vaginal retention time of the 
drug. 
MATERIALS AND METHODS  
Materials 
Tioconazole was kindly supplied by Pfizer Company, Egypt. Ethyl 
cellulose N14, carbopol 940 (Cbp 940) and HPMC K100 M were 
kindly supplied by EIPICO Company, Egypt. Tween80, methylene 
chloride, methanol and potassium dihydrogen orthophosphate were 
purchased from El-Nasr Company, Egypt. All other chemicals were of 
analytical grade. 
 
Table 1: Composition of different tioconazole microspheres formulations 
Formulation code Drug: ehylcelluloseN14 ratio Drug: HPMCK100M ratio Cbp 940 (%W/W) Tween 80 
(%W/V) 
Time (h) RPM 
F1 1:1   0.5 1 1000 
F2 1:3   0.5 1 1000 
F3 1:5   0.5 1 1000 
F4  1:1  0.5 1 1000 
F5  1:3  0.5 1 1000 
F6  1:5  0.5 1 1000 
F7  1:5 1 0.5 1 1000 
F8  1:5 2 0.5 1 1000 
F9 1:5  1 0.5 1 1000 
F10 1:5  2 0.5 1 1000 
Cbp 940: Carbopol 940, HPMC: Hydroxy propyl methyl cellulose 
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Preparation of vaginal mucoadhesive microspheres 
Microspheres were prepared by the emulsion solvent evaporation 
method. The drug and the polymer were accurately weighed by 
electron digital balance (Metter-Toledo, Ag, CH 8606, Greifense, 
Switzerland), and were dissolved into 20 ml methylene chloride at 
ambient room temperature. The organic phase was slowly added to 
100 ml distilled water containing 0.5 % (W/V) Tween80 and 
emulsified by stirring at 1000 RPM using a mechanical stirrer 
(Heidolph PZP-2000, Germany) for 1 h. The solution was filtered, 
washed and dried overnight at ambient room temperature [6]. 
The composition of the different tioconazole microspheres 
formulations is given in table 1. 
Characterization of microspheres 
Particle size analysis 
The particle size of microspheres was determined by counting 100 
microspheres by using a calibrated optical microscope [7]. 
Yield percentage 
The prepared microspheres were collected, dried and weighed. The 
actual weight was divided by the total weight of the starting 





Drug entrapment efficiency 
Microspheres equivalent to 10 mg of the drug were crushed, 
suspended in 20 ml phosphate buffer pH4.5 and stirred at 100 RPM 
at ambient room temperature in a thermostatic shaker water bath 
(Julabo SW-20 C, Germany) till equilibrium. Then, the solution was 
filtered, suitably diluted and the drug content was determined by 
RP-C18 HPLC method using methanol: phosphate buffer (70:30) 
adjusted to pH 4 by orthophosphoric acid as a mobile phase at a flow 
rate of 1.5 ml/min and UV detection at 260 nm. The experiment was 






The extent of the swelling was expressed as the percentage weight 
gained by the microspheres. 20 mg of each formula was kept in a 
petri dish containing phosphate buffer pH 4.5 at ambient room 
temperature for 4 h. At the end of the experiment, the microspheres 
were withdrawn and weighed. The swelling index was determined 





Where W0 is the weight of the dried microspheres and Wt is the 
weight of the swollen microspheres after 4 h. The experiment was 
done in triplicate [9]. 
Mucoadhesion strength measurement  
The mucoadhesion strength was estimated by measuring the force 
required to detach the microspheres from the mucin disc in between 
two vials using a modified balance. The modified apparatus 
composed of a two-arm balance, one side of which contained a 
plastic jar, and the other side contained two glass vials, one of the 
vials was attached permanently to the base of the stage, and the 
other was attached to the arm of the balance by a thick strong 
thread. Two mucin discs (E) were secured to the two glass vials (C) 
separately using a cyanoacrylate adhesive and a rubber band (fig.1). 
The microspheres (0.5 g) were applied to the mucin disc between 
the two vials. The height of the vial adjusted so that the spheres 
could adhere to the surface of both vials then, a constant weight was 
applied on the upper vial for 2 min, after which, it was removed and 
the upper vial was connected to the balance. Water was added 
slowly at a constant rate to a plastic jar (13–15 drops per min), until 
both vials were separated. The mucoadhesion strength, expressed as 
the detachment stress in dynes/cm2 was determined using the 
following equation:  




Where m is the weight of water (g) that detached the two vials, gr is 
the acceleration due to gravity taken as 980 cm/s2, A (cm2) is the 
area of the mucin exposed and is equal to πr2 (r is the radius of the 
exposed mucin). The experiment was done in triplicate. 
 
 
Fig. 1: Modified balance for measuring mucoadhesion strength: (A) 
Modified balance; (B) Plastic jar; (C) Glass vial; (D) Microspheres 
formulation; (E) Mucin; (F) Height-adjustable pan [11] 
 
PH determination 
10 mg of each formula was allowed to swell for 3 h in 25 ml distilled 
water. The pH of the solution was determined using a pH meter 
(JENCO Model-5005 USP). The experiment was done in triplicate. 
In vitro release study 
The cumulative release percentage of tioconazole microspheres 
were carried out in phosphate buffer pH4.5 for 8 h in USP-type II 
dissolution apparatus at 37±0.5 ° C and 100 RPM. Microspheres 
equivalent to 10 mg drug were used in this study. The samples were 
taken hourly and replaced with an equal volume of fresh release 
medium to maintain sink condition. After suitable dilution, samples 
were analyzed using HPLC-UV detection at 260 nm [12]. 
In vitro antifungal activity 
In vitro antifungal activity of tioconazole loaded microspheres was 
investigated by the agar diffusion disc method [13]. Exactly four 
cups of 10 mm diameter were made in sabourated dextrose agar 
after inoculation with Candida Albicans. Two cups were filled with a 
calculated amount of selected microspheres and 0.5 ml distilled; 
sterilized water was added for microspheres wettability. The other 
two cups were filled with tioconazole solution as a positive control 
and the drug-free spheres as a negative control. The plates then 
were incubated at 25 ° C for 72 h. The radius of the inhibition zones 
was calculated and compared [14]. 
Kinetic analysis of the data 
The data of the drug release from the tested microspheres 
formulations were subjected to theoretical analysis, to determine 
the order of kinetic release according to the following equations:  
• Zero-order kinetic. CT = Co–Kt. 
• First order kinetic. Log CT =  Log	Co		Kt	
2.303
 
• Diffusion control model. Q/A=2 Co (A/π)½t½ 
Statistical analysis of the data 
Experimental results were expressed as the mean±SD (standard 
deviation of the mean). One-way analysis of variance (ANOVA) was 
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applied to check the significance. Differences were considered to be 
statistically significant at p<0.05 [15]. 
RESULTS AND DISCUSSION 
Spherical, uniform and smooth surface microspheres were obtained 
as demonstrated in fig. 2 
 
 
Fig. 2: Photomicrograph of 1:5 HPMC K100M (1:5, 0.5% Tween 
80, 1000 RPM, 640 x 320 pixels) 
 
Particle size 
The mean particle size of the prepared tioconazole microspheres is 
given in tables 2, 4, and 5. It is greatly obvious that microspheres 
which were prepared with ethyl cellulose N14 (F1, F2, F3) were 
smaller than those prepared with HPMC K 100 M (F4, F5, F6), and this 
could be attributed to the impact of the polymer solution viscosity. 
As a drug to polymer ratio was increased from 1:1 to1: 5, there was a 
comparable and significant increase in the mean particle size from 
267±4.2 µm (F1) to 400±3.5 µm (F3) and from 297±6.1 µm (F4) to 
435±7.8 µm (F6).  
This was in a good agreement with the results of Sabry et al. [16] 
who found that as a drug to polymer ratio was increased from 1:1 to 
1:5, the size of nizatidine micro balloons significantly increased from 
230±1.9 to 324±2.6 respectively. 
The increase in the polymer concentration resulted in an increase in 
the viscosity of the polymer solution and consequently larger 
particles were formed [17]. 
As the stirring rate was increased from 1000 to 1600 RPM, the 
particle size significantly decreased from 400±3.5 µm to 315±5.9 µm 
and from 435±7.8 µm to 335±6.3 µm, for F3 and F6 respectively. 
This may be due to the high shear force associated with the high 
speed which splits the larger droplets into smaller ones [16, 18]. 
The increase in Tween80 concentration from 0.5% to 1.5% resulted 
in a significant decrease in the particle size from 400±3.5 µm to 
310±6.7 µm and from 435±7.8 µm to 332±5.3 µm for F3 and F6 
respectively. Higher surfactant concentration reduces microspheres 
aggregation [16, 18]. Addition of Cbp940 had a non-significant effect 
on the particle size. 
Entrapment efficiency 
The results in table 2 show that the mean entrapment efficiency for 
F1, F2, F3, F4, F5, and F6 were 55.0±1.5, 75.2±0.8, 88.4±2.5, 
69.2±2.1, 85.1±3.1, and 97.8±1.6 respectively. It is clear that there 
was a significant increase in the drug entrapment with an increase in 
the polymer concentration. 
This was in a great accordance with Kalita et al. who found that 
metronidazole entrapment increased with an increase in HPMC K4 
M concentration [4]. 
The increase in the polymer concentration resulted in an increase in 
the viscosity of the polymer solution which produced larger particles 
and consequently much drug was entrapped [8]. 
There was a reduction in the entrapment efficiency from 88.4±2.5 to 
50.1±2.1, and from 97.8±1.6 to 63.6±2.6, for F3 and F6 respectively 
(table 4) with an increase in the stirring rate from 1000 to 1600 
RPM. Higher stirring rate resulted in smaller particle size 
microspheres which entrap less drug.  
As surfactant concentration increased from 0.5% to 1.5%, there was 
a significant decrease in the entrapment efficiency from 88.4±2.5 to 
65. 1±1.9, and from 97.8±1.6 to 73.1±2.1, for F3 and F6 respectively 
(table 5). The intact and smooth microspheres will be formed at a 
low surfactant concentration, but as the concentration increased, the 
microspheres become more brittle and much drug will be lost during 
washing [19]. The addition of Cbp940 had a non-significant effect on 
the drug entrapment. 
Yield percentage 
Table 2 demonstrates the effect of the polymer concentration on the 
production yield percentage. When the drug to polymer ratio was 
increased from 1:1 to1: 5, there was a significant increase in the 
yield percentage from 59.1±1.3 (F1) to 85.0±2.3 (F3), and from 
65.1±1.3 (F4) to 95. 2±1.2 (F6). A significant reduction in the yield 
percentage with the increase of either stirring rate [18] or surfactant 
concentration [20] was observed (tables 4 and 5). This could be 
ascribed to the formation of smaller particles which were lost during 
the filtration and the collection of the microspheres. It was found 
that the addition of Cbp940 had a non-significant effect on the yield 
percentage. 
Mucoadhesion strength 
Table 3 demonstrates mucoadhesion strength of the prepared 
microspheres formulae. The results showed that the microspheres 
which were prepared with HPMC K100 M (F4, F5, and F6), showed 
mucoadhesion of 32.5±1.2, 38.1±1.6, and 45.6±1.2 respectively. 
These results were greater than those of ethyl cellulose N14 
microspheres (F1, F2, F3), which were 20.6±0.1, 26.7±1.2, and 
31.5±1.6 respectively. This could be attributed to several factors. 
The hydroxyl groups' content of HPMC K100 M is greater than that 
of ethyl cellulose N14 which allows more swelling, resulting in an 
increase in the flexibility and consequently has more distance 
between its chains, which gives more hydrogen bonding with the 
substrate [21]. Also, HPMC K100 M has a molecular weight higher 
than that of ethyl cellulose N14 which suggests more adherence to 
the substrate [22, 23]. The results also inferred that as the polymer 
concentration was increased, there was a corresponding and 
significant increase in the mucoadhesion strength [24].  
The addition of Cpb940 (F7, F8, F9, F10) produced a significant 
increase in the mucoadhesion and this could be ascribed to either 
the increased hydrogen bonding or the molecular weight or both. 
Swelling percentage 
The results in table 3 declare that the swelling percentages of ethyl 
cellulose microspheres F1, F2 and F3 were 120.5±1.5, 131.6±0.9, 
and 143.1±1.3 respectively and those of HPMC microspheres 
were133. 1±2.3, 141.6±1.6, and 154.2±0.8 respectively. The 
obtained results inferred that the swelling of HPMC is higher than 
that of ethyl cellulose, and this could be ascribed to the higher 
hydrophilicity of the former than the later [21]. Also, the swelling 
percentage significantly increased with an increase in the polymer 
concentration [25]. Iswarriya et al. reported an increase in the 
swelling of ranolazine micro balloons with an increase in sodium 
alginate concentration [26].  
The addition of 1% Cbp940 increased the swelling from154. 2±0.8 
(F6) to160. 2±1.9 (F7) and from143. 1±1.3 (F3) to150. 6±0.9 (F9). 
Further increase in Cbp940 concentration to 2%, resulted in a 
significant increase to 173.2±2.1 and 159. 6±2.1 for F8 and F10 
respectively.  
PH 
The pH of the vagina falls within the range of 4 to 5 and that of all 
prepared formulae was within the range of 4.6 to 5.9, which ensures 
non-irritability to the vaginal mucosa. 
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Table 2: Particle size, yield percentage and entrapment efficiency of mucoadhesive microspheres 
Formulation code Mean particle size (µm)±SD* Mean yield percentage)±SD* Mean entrapment efficiency (%)±SD* 
F1 267±4.2 59.1±1.3 55.0±1.5 
F2 334±5.6 70.2±2.1 75.2±0.8 
F3 400±3.5 85.0±2.3 88.4±2.5 
F4 297±6.1 65.1±1.3 69.2±2.1 
F5 352±3.9 83.1±2.6 85.1±3.1 
F6 435±7.8 95.2±1.2 97.8±1.6 
F7 415±5.6 96.6±2.7 96.2±1.3 
F8 425±6.2 95.6±1.9 98.1±1.5 
F9 395±5.1 86.7±1.9 85.6±1.5 
F10 405±7.1 88.6±2.1 89.1±2.5 
*Mean of three determinations±standard deviations of the mean. 
 
Table 3: Mucoadhesion strength, swelling after 4 h and PH of mucoadhesive microspheres 
Formulation code Mucoadhesion strength (*103dyne/cm2)±SD* Swelling (%) after 4 h±SD* PH±SD* 
F1 20.6±0.1 120.5±1.5 4.7±0.2 
F2 26.7±1.2 131.6±0.9 4.9±0.8 
F3 31.5±1.6 143.1±1.3 4.7±0.1 
F4 26.8±0.9 133.1±2.3 4.9±0.5 
F5 32.5±1.2 141.6±1.6 5.3±0.1 
F6 38.1±1.6 154.2±0.8 4.6±0.5 
F7 45.6±1.2 160.2±1.9 4.7±0.8 
F8 51.6±0.9 173.2±2.1 4.6±0.1 
F9 36.2±1.2 150.6±0.9 5.1±0.1 
F10 43.5±0.8 159.6±2.1 4.9±0.8 
*Mean of three determinations±standard deviations of the mean. 
 
Table 4: Effect of stirring rate on particle size, yield percentage and entrapment efficiency 
Formulation code RPM Mean particle size (µm)±SD* Mean yield percentage)±SD* Mean entrapment efficiency (%)±SD* 
F3 1000 400±3.5 85.0±2.3 88.4±2.5 
1200 355±6.5 72.0±1.6 73.5±1.1 
1600 315±5.9 59.2±2.1 50.1±2.1 
F6 1000 435±7.8 95.2±1.2 97.8±1.6 
1200 385±7.2 83.1±2.1 81.6±2.1 
1600 335±6.3 70.5±1.5 63.6±2.6 
*Mean of three determinations±standard deviations of the mean. 
 









Mean entrapment efficiency 
(%)±SD* 
F3 0.5 400±3.5 85.0±2.3 88.4±2.5 
1.0 352±6.1 74.6±1.7 76.3±1.6 
1.5 310±6.7 61.6±2.1 65.1±1.9 
F6 0.5 435±7.8 95.2±1.2 97.8±1.6 
1.0 385±5.3 86.2±1.6 85.1±2.5 
1.5 332±5.3 76.4±1.5 73.1±2.1 
*Mean of three determinations±standard deviation of the mean. 
 
In vitro release study 
The release of tioconazole from all prepared microspheres formulations 
followed Higuchi diffusion model. The effect of the polymer type and 
polymer concentration is shown in fig. 3 and 4. It is obvious that the 
cumulative release percentages of the drug from F1, F2 and F3 were 
greater than those from F4, F5 and F6. The increase of the drug to 
polymer ratio from 1:1 to 1:5, resulted in a significant decrease in the 
percentage of tioconazole which released after 8 h from 74.1±0.6 (F4) to 
58.4±0.3 (F6), and from 88.2±0.5 (F1) to 72.8±0.3 (F3). 
The increase of the polymer concentration increases the swelling of 
the polymer matrix and the diffusional path length, which might 
delay the release [27-29]. 
The hydration capacity of the polymer increased with the addition 
of Cbp940. It formed a gelatinous mass when came into contact 
with the dissolution medium and retarded the release of the drug 
[30]. This explains the decrease in the cumulative release 
percentage upon adding Cbp940 (fig. 5 and 6). Sarfaraz reported a 
decrease in rifampicin release from 91.2% to 81.7% with the 
increase of drug to Cbp974 ratio from 1: 1 to 1:2 [31]. The 
increase of the stirring rate from 1000 to 1600, resulting in an 
increase in the cumulative release percentages from 58.4±0.3 to 
79.1±0.8 and from 72.8±0.3 to 90.2±0.9, for F6 and F3 
respectively (fig. 7and 8). Smaller microspheres with the larger 
surface area were formed at a higher stirring rate, which 
suggested the increase in the cumulative release percentage 
after 8 h [20]. Fig. 9 and 10 show that an increase in the 
surfactant concentration to 1.5% increased the cumulative 
release to 78.1±and 87.6±0.5, for F3 and F6 respectively. The 
increased surfactant concentration gave porous microspheres 
which resulted in higher release percentages [19, 32]. 
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Fig. 3: Effect of tioconazole: ethyl cellulose ratio on the cumulative release of tioconazole, Number of experiments=3 
 
 
Fig. 4: Effect of tioconazole: HPMC ratio on the cumulative release of tioconazole, number of experiments=3 
 
 
Fig. 5: Effect of Cbp940 on the cumulative release of tioconazole from ethyl cellulose microspheres, number of experiments=3 
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Fig. 6: Effect of Cbp940 on the cumulative release of tioconazole from HPMC microspheres, number of experiments=3 
 
 
Fig. 7: Effect of stirring rate on the cumulative release of tioconazole from ethyl cellulose microspheres, number of experiments=3 
 
 
Fig. 8: Effect of stirring rate on the cumulative release of tioconazole from HPMC microspheres, number of experiments=3 
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Fig.10: Effect of Tween 80 concentration on the cumulative release of tioconazole from HPMC microspheres, number of experiments=3 
 
In vitro antifungal activity 
The results in table 6, fig. 11 and 12 exhibit the inhibition zones of 
the tested formulae F3 and F6 respectively. Tioconazole free 
microspheres showed zero inhibition zones, which indicated non 
anti-fungal activity. 
Tioconazole solution showed an inhibition zone of 43±2.6 mm. For F3 
and F6, the inhibition zones were 47.6±0.6 and 52.3±1.5 respectively. 
From the previous results, it can be concluded that both ethyl 
cellulose and HPMC loaded tioconazole mucoadhesion microspheres 
produced a significant antifungal activity against Candida Albicans. 
 
 
Fig.11: Inhibition zones of F3 and tioconazole, number of 
experiments=3 
a=tioconazole free ethyl cellulose microspheres, b= Tioconazole 
solution, c and d=F3 
 
Fig.12: Inhibition zones of F6 and tioconazole, number of 
experiments=3 
a=tioconazole free HPMC microspheres, b= Tioconazole solution, c 
and d=F6 
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Table 6: In vitro antifungal activity of tioconazole formulations 
Formula  Zone of inhibition (mm)±S. D* 
Tioconazole solution 43±2.6 
Tioconazole free ethyl cellulose microspheres, control 0 
Tioconazole free HPMC microspheres, control 0 
F3 47.6±0.5 
F6 52.3±1.5 
*Mean of three determinations±standard deviations of the mean. 
 
CONCLUSION 
Both ethyl cellulose and HPMC mucoadhesive microspheres had 
achieved the goal of this study through an increase in the retention 
time of the drug inside the vagina, which reflected by the high 
mucoadhesion strength, the delayed release and the significant anti-
fungal activity against Candida Albicans. It can be concluded that 
both ethyl cellulose and HPMC mucoadhesive microspheres are 
considered promising tools to enhance both the vaginal availability 
and bioavailability. 
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